A new clinical trial for patients with acute myeloid leukemia will open at the Huntsman Cancer Institute. This trial consisting of eight academic centers will conduct a quick molecular genetic test to guide physicians in the appropriate treatment. This personalized treatment protocol should enhance the effectiveness in AML therapy. The trial seeks to enroll 500 subjects and is estimated to be completed in 2021. Dr. Mike Deininger, Dr. Tibor Kovacsovics and Dr. Paul Shami will lead the clinical trial at the Huntsman Cancer Institute.